

# **Product datasheet for TL317599V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ZNRF3 Human shRNA Lentiviral Particle (Locus ID 84133)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ZNRF3 Human shRNA Lentiviral Particle (Locus ID 84133)

**Locus ID:** 84133

Synonyms: BK747E2.3; RNF203

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** ZNRF3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001206998, NM 032173, NM 032173.2, NM 032173.3, NM 001206998.1, NM 032173.1,

BC009252, BC021570, BC042614, BC051344, BC069019, BC094857, BC167805,

NM 001206998.2

UniProt ID: Q9ULT6

**Summary:** E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by

mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6. Acts on both canonical and non-canonical Wnt signaling pathway. Acts as a tumor suppressor in the intestinal stem cell zone by inhibiting the Wnt

signaling pathway, thereby resticting the size of the intestinal stem cell zone

(PubMed:22575959). Along with RSPO2 and RNF43, constitutes a master switch that governs

limb specification (By similarity).[UniProtKB/Swiss-Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>.

If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).